Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

LENZ Therapeutics, Inc. (LENZ)

NMS · Biotechnology

$5.88+0.18 (+3.16%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$184.4M
P/E (TTM)
EPS
$-3.76
Div Yield
52W Range
$4.68–$50.40
Beta
1.62

Company overview

Next earnings: 2026-07-29(1d)

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Peers in Biotechnology

All in industry →

Recent press releases

LENZ Therapeutics, Inc. has not issued a press release in this window.

SEC filings

All filings →

LENZ Therapeutics, Inc. has not filed an SEC document in this window.

LENZ Therapeutics, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
4,178,823 sh0.0%
3,612,211 sh0.0%
2,656,888 sh0.0%
FMR LLC$59.2M
3,702,718 sh+4140.7%
1,692,006 sh+14.8%
1,321,202 sh-0.7%
1,017,751 sh0.0%
1,571,738 sh+30.8%

People at LENZ Therapeutics, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$14.6M
06/25
$5.0M
NI -$14.9M
09/25
$12.5M
NI -$16.7M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.59
Prior: $-0.53
Revenue sparkline